Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Research Highlight
  • Published:

Therapy

Shifting targets for eosinophilic oesophagitis

Nature Reviews Gastroenterology & Hepatology volume 21, page 605 (2024)Cite this article

Subjects

Two phase III trials of new drugs for eosinophilic oesophagitis (EoE) have been reported in The New England Journal of Medicine. The findings not only highlight new treatments for the condition, but also potentially shift the emphasis for future therapeutic targets and diagnostic criteria.

In the first trial (EoE KIDS), Mirna Chehade and colleagues assessed dupilumab, a human monoclonal antibody that blocks IL-4 and IL-13 pathways, for EoE in patients aged 1–11 years. “Dupilumab was approved in the US to treat children with EoE 12 years and older in May 2022. FDA approval was then extended to treat children 1 year and older weighing at least 15 kg in January 2024,” explains Chehade, who adds that these new results provide the basis of this recent FDA approval. In this phase III trial, paediatric patients with active EoE (n = 102; mean age 7.1 years; 76% boys, 24% girls) were randomly assigned 2:2:1:1 to receive weight-tiered higher-exposure dupilumab, lower-exposure dupilumab or placebo for 16 weeks (part A), followed by a 36-week extension period active treatment phase in which eligible patients in each dupilumab group continued the same regimen and those in the placebo groups were assigned to either lower-exposure or higher-exposure dupilumab (part B).

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on SpringerLink
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

References

Original articles

  • Chehade, M. et al. Dupilumab for eosinophilic esophagitis in patients 1 to 11 years of age. N. Engl. J. Med. 390, 2239–2251 (2024)

    Article  PubMed  Google Scholar 

  • Rothenburg, M. E. et al. Eosinophil depletion with benralizumab for eosinophilic esophagitis. N. Engl. J. Med. 390, 2252–2263 (2024)

    Article  Google Scholar 

Related article

  • Biedermann, L. & Straumann, A. Mechanisms and clinical management of eosinophilic oesophagitis: an overview. Nat. Rev. Gastroenterol. Hepatol. 20, 101–119 (2023)

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Nature Reviews Gastroenterology & Hepatology http://www.nature.com/nrgastro/

    Katrina Ray

Authors
  1. Katrina Ray
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Katrina Ray.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Ray, K. Shifting targets for eosinophilic oesophagitis. Nat Rev Gastroenterol Hepatol 21, 605 (2024). https://doi.org/10.1038/s41575-024-00969-2

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/s41575-024-00969-2

Search

Advanced search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing